E2F2 and prostate carcinoma: E2F2 has been well-characterized as a regulator of the G1-to-S-phase transition, it has been confirmed that it may be novel therapeutic candidate for prostate cancer given its ability to induce cell-cycle arrest and inhibit cell growth.